Indivior PLC (NASDAQ:INDV) Receives $39.33 Consensus Target Price from Brokerages

Indivior PLC (NASDAQ:INDV) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $39.3333.

Several research firms have recently weighed in on INDV. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. HC Wainwright increased their target price on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a report on Monday, January 12th. Morgan Stanley restated an “overweight” rating and set a $36.00 price target on shares of Indivior in a research note on Wednesday, December 3rd. Northland Securities set a $50.00 price target on shares of Indivior in a research report on Tuesday, January 20th. Finally, Weiss Ratings raised shares of Indivior from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday.

Insider Activity at Indivior

In other news, Director David E. Wheadon purchased 1,771 shares of the stock in a transaction on Monday, January 5th. The shares were acquired at an average price of $35.39 per share, with a total value of $62,675.69. Following the completion of the acquisition, the director directly owned 14,395 shares of the company’s stock, valued at $509,439.05. This trade represents a 14.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Keith Humphreys acquired 775 shares of the stock in a transaction dated Monday, January 5th. The stock was acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the transaction, the director directly owned 5,802 shares of the company’s stock, valued at approximately $205,332.78. This represents a 15.42% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 4,871 shares of company stock worth $172,385 in the last 90 days.

Institutional Trading of Indivior

A number of institutional investors and hedge funds have recently bought and sold shares of INDV. Oaktree Capital Management LP boosted its holdings in shares of Indivior by 2,241.6% during the 3rd quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock valued at $6,215,206,000 after purchasing an additional 246,776,273 shares during the last quarter. Divisadero Street Capital Management LP lifted its position in shares of Indivior by 2,372.5% in the third quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock worth $81,072,000 after buying an additional 3,226,605 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its position in shares of Indivior by 101.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock worth $228,611,000 after buying an additional 3,201,639 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Indivior during the fourth quarter valued at approximately $82,687,000. Finally, Vanguard Group Inc. boosted its stake in Indivior by 57.9% during the fourth quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock valued at $196,403,000 after buying an additional 2,008,078 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.

Indivior Price Performance

Shares of NASDAQ:INDV opened at $32.27 on Wednesday. Indivior has a 1-year low of $8.64 and a 1-year high of $38.00. The business has a fifty day moving average price of $34.11 and a 200-day moving average price of $30.29. The company has a market capitalization of $4.04 billion, a PE ratio of 19.68 and a beta of 0.83.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.17. The company had revenue of $358.00 million during the quarter, compared to the consensus estimate of $305.62 million. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. On average, sell-side analysts anticipate that Indivior will post 1.22 earnings per share for the current fiscal year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.